Journal of Controlled Release最新文献

{"title":"Expression of concern to: Journal of Controlled Release 140 (2009) 148-156.","authors":"","doi":"10.1016/j.jconrel.2026.115113","DOIUrl":"https://doi.org/10.1016/j.jconrel.2026.115113","url":null,"abstract":"","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"396 ","pages":"115113"},"PeriodicalIF":12.4,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery","authors":"Amin Ariaee ,&nbsp;Karim Noueihad ,&nbsp;Alex Hunter ,&nbsp;Anthony Wignall ,&nbsp;Hannah R. Wardill ,&nbsp;Maya Davies ,&nbsp;Clive A. Prestidge ,&nbsp;Paul Joyce","doi":"10.1016/j.jconrel.2026.114711","DOIUrl":"10.1016/j.jconrel.2026.114711","url":null,"abstract":"<div><div>Semaglutide (SEM) is a glucagon-like peptide-1 (GLP-1) receptor agonist formulated for oral delivery with the absorption enhancer salcaprozate sodium (SNAC). Although oral SEM achieves 0.4–1% bioavailability through gastric epithelial uptake, gastrointestinal (GI) adverse events remain a major cause of therapy discontinuation. This study examined the effects of SEM (0.74 mg/kg/day), SNAC (22 mg/kg/day), and combined SEM–SNAC (1:33 <em>w</em>/w) treatments on microbiota and metabolic function, in healthy Sprague Dawley rats over 21 days. Whilst microbial α-diversity remained stable, SNAC significantly altered β-diversity (PERMANOVA, <em>p</em> &lt; 0.05) and depleted primary fermenters in <em>Muribaculaceae</em> (−62%) and <em>Bacteroidaceae</em> (−77%) compared to the control group. These compositional changes correlated with reduced predicted saccharolytic enzyme abundance and fecal butyrate concentrations (−77% SNAC, −75% SEM–SNAC). Plasma cytokine analysis showed elevated tumor necrosis factor-α (TNF-α, 70%) and suppressed brain-derived neurotrophic factor (BDNF, 85%), consistent with changes in circulating inflammatory and neurotrophic markers from SNAC monotherapy. SNAC-treated animals also exhibited increased liver weight and reduced caecum mass, occurring alongside microbiota compositional changes and altered fermentation-associated markers. Spearman correlations linked <em>Muribaculaceae</em> and <em>Bacteroidaceae</em> loss with decreased saccharolytic enzyme abundance, lower SCFA levels, and increased TNF-α. While these findings are associative and require mechanistic validation, they indicate that chronic SNAC exposure is linked to concurrent microbial, metabolic, and inflammatory marker changes in healthy rats, highlighting the potential need for alternative, microbiota-safe strategies for oral peptide delivery.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114711"},"PeriodicalIF":11.5,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146146641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage membrane-biomimetic DNA nanocages deliver taurine to reprogram trained immunity for periodontitis therapy","authors":"Ya Cui ,&nbsp;Xiaojing Li ,&nbsp;Shebin Hong ,&nbsp;Kaili Lin ,&nbsp;Lixia Mao ,&nbsp;Xudong Wang","doi":"10.1016/j.jconrel.2026.114664","DOIUrl":"10.1016/j.jconrel.2026.114664","url":null,"abstract":"<div><div>As one of the most burdensome oral diseases, periodontitis frequently leads to tooth loss and heightens the risk of systemic diseases. A major clinical challenge is that current strategies often fail to resolve chronic inflammation and bone resorption characteristic of its refractory state. Recent research implicates maladaptive trained immunity (TRIM) as a core mechanism, which promotes myeloid cell skewing and amplifies inflammatory responses and bone loss. Single-cell sequencing of peripheral blood mononuclear cells from periodontitis patients identified an elevated inflammatory stress state. Taurine, a sulfur-containing amino acid with known anti-inflammatory properties, offers therapeutic potential, but its application is limited by low oral bioavailability and a lack of target specificity. To address these challenges, a novel therapeutic strategy based on precisely engineered DNA nanocages carrying taurine has been developed. These nanocages are camouflaged with hybrid cell membranes harvested from M2-polarized and trained-immunosuppressive macrophages for targeted monocytes. This biomimetic system is designed to therapeutically correct the dysregulated TRIM state in monocytes and macrophages, effectively inhibiting inflammation and bone destruction. Concurrently, it restores the osteogenic differentiation and mitochondrial function of periodontal ligament cells via immune modulation, establishing a novel strategy for the precise immunotherapy of chronic periodontitis.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114664"},"PeriodicalIF":11.5,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146048493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-payload small-molecule drug conjugates enable bystander anticancer activity with reduced nonspecific release","authors":"Chuanjie Chen ,&nbsp;Yongzhang Pan ,&nbsp;Na Zhang ,&nbsp;Ting Yang ,&nbsp;Jiaxin Shi ,&nbsp;Bige Ren ,&nbsp;Yonghan He ,&nbsp;Xuan Zhang","doi":"10.1016/j.jconrel.2026.114695","DOIUrl":"10.1016/j.jconrel.2026.114695","url":null,"abstract":"<div><div>Small-molecule drug conjugates (SMDCs) have emerged as a promising class of targeted therapeutics, yet their clinical translation has been hindered by suboptimal efficacy and safety, with conventional optimization largely restricted to variations in ligand design and linker chemistry. We propose a dual-payload strategy that enhances therapeutic efficacy while concurrently minimizing off-target diffusion that contributes to systemic toxicity. In this proof-of-concept study, a representative SMDC bearing two degrader payloads, termed Bi-LIVTAC (XZ1618), demonstrates improved targeted cytotoxicity and a robust bystander effect, accompanied by a significant reduction in receptor-independent uptake. Notably, XZ1618 achieves complete tumor regression in combination with sorafenib in a Huh-7 xenograft model, thereby markedly expanding the therapeutic window without inducing hematological toxicity or organ damage. Moreover, this dual-payload design is broadly applicable to SMDCs targeting other membrane receptors, such as folate receptor, and to diverse payload types, including conventional cytotoxins and fluorescent probes. These findings establish the dual-payload strategy as a versatile and translatable platform for developing next-generation SMDCs with improved therapeutic windows.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114695"},"PeriodicalIF":11.5,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146134053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wound healing under the regulation of mechanically active biomaterials: From mechanism exploration to scar prevention","authors":"Huiqi Zhang ,&nbsp;Dong Luo ,&nbsp;Guojun Cai ,&nbsp;Manman Hu ,&nbsp;Zhen Fan ,&nbsp;Meng Li","doi":"10.1016/j.jconrel.2026.114700","DOIUrl":"10.1016/j.jconrel.2026.114700","url":null,"abstract":"<div><div>Severe cutaneous injury predictably culminates in scar formation, typified by the loss of skin appendages and a consequent impairment of both structural integrity and physiological function. A growing body of evidence now indicates that mechanical cues are as determinative as biochemical signals in directing cutaneous repair and scar formation. Accordingly, mechanomodulatory biomaterials have emerged as promising platforms for promoting scar-free wound repair. However, the mechanistic bases by which mechanical forces remodel the extracellular milieu—and how such forces can be rationally exploited to reprogram mechanotransductive signaling—remain incompletely resolved. This knowledge gap poses a major barrier to the clinical translation of mechanotherapeutic approaches. In this review, we synthesize current understanding of cutaneous biomechanics and its intimate interplay with wound-healing cascades, and we delineate the principal mechanotransduction pathways that convert physical stimuli into cellular fate decisions. We further provide a critical appraisal of recent advances in mechanically active dressings designed to deliver spatially and temporally controlled mechanical cues that bias tissue repair toward regeneration. Finally, we identify outstanding challenges and propose future directions for the development of mechanoregulated biomaterials, offering a strategic roadmap to accelerate the translation of scarless healing strategies into clinical practice.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114700"},"PeriodicalIF":11.5,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146134058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationalizing nose-to-brain drug delivery: Machine learning-guided optimization and mechanistic elucidation of olfactory deposition for nasal sprays","authors":"Zizhao Zhai ,&nbsp;Wenhao Wang ,&nbsp;Guanlin Wang ,&nbsp;Chunfu Wei ,&nbsp;Shuhua Wei ,&nbsp;Jinxia Li ,&nbsp;Lingling Zheng ,&nbsp;Xiao Yue ,&nbsp;Chuangxin Chen ,&nbsp;Junhuang Jiang ,&nbsp;Bing Zhu ,&nbsp;Ziyu Zhao ,&nbsp;Xin Pan ,&nbsp;Chuanbin Wu ,&nbsp;Xuejuan Zhang","doi":"10.1016/j.jconrel.2026.114667","DOIUrl":"10.1016/j.jconrel.2026.114667","url":null,"abstract":"<div><div>Nose-to-brain drug delivery <em>via</em> nasal sprays is severely limited by low olfactory deposition. In this study, we integrate machine learning with high-throughput experimentation to systematically optimize olfactory deposition of solid lipid nanoparticle-loaded nasal sprays (SLN-NS). By engineering the dispersed medium properties using five excipients at varying concentrations across 40 formulations, we establish a three-level interlocking correlation among dispersed medium properties, spray performance, and olfactory deposition. We demonstrate that basic physicochemical properties predominantly influence microscopic droplet characteristics, while dynamic rheological parameters dictate macroscopic spray morphology. A random forest model accurately predicted olfactory deposition and guided the design of an optimized formulation, achieving 19.77% olfactory deposition, representing a 4 to 20-fold improvement over conventional nasal sprays. <em>In vivo</em> studies confirmed enhanced brain delivery and superior therapeutic efficacy in animal models of migraine, Alzheimer's, and Parkinson's diseases. This work provides a rational framework for optimizing nasal spray formulations to overcome anatomical barriers for improved CNS drug delivery.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114667"},"PeriodicalIF":11.5,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146072208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large and low-PEG lipid nanoparticles enable efficient dendritic cell targeting for potent mRNA Cancer vaccines","authors":"Xiaolan Xu ,&nbsp;Jiahao An ,&nbsp;Dan Bai ,&nbsp;Yuanchao Xu ,&nbsp;Tingting Wu ,&nbsp;Hua Yang ,&nbsp;Yueyue Yan ,&nbsp;Shaojun Yang ,&nbsp;Zifan Wei ,&nbsp;Yuchen Yao ,&nbsp;Qian Liu ,&nbsp;Tao Xu ,&nbsp;Lan Zhu","doi":"10.1016/j.jconrel.2026.114680","DOIUrl":"10.1016/j.jconrel.2026.114680","url":null,"abstract":"<div><div>Efficient delivery of messenger RNA (mRNA) to dendritic cells (DCs) remains a major challenge limiting the efficacy of mRNA cancer vaccines. Here, we report a large-sized lipid nanoparticle (LLNP) platform specifically engineered for enhanced DC targeting. By reducing PEG–lipid content to 0.3% and proportionally increasing the concentrations of structural lipids and mRNA sixfold relative to the Moderna classic formulation, we generated LLNPs with enlarged size and optimized surface properties that favor DC uptake. Following intravenous administration, LLNPs achieved markedly enhanced mRNA expression in DCs, with ∼82% of GFP⁺ cells identified as DCs and ∼ 44% of CD11c⁺ DCs expressing GFP. LLNPs also promoted DC maturation and antigen presentation. LLNP-mediated delivery of HPV16 E6E7 mRNA elicited robust effector and memory cytotoxic T lymphocyte responses, enabling effective tumor regression at doses as low as 1 μg. Both conventional type 1 dendritic cells (cDC1) and conventional type 2 dendritic cells contributed to antigen presentation, with cDC1 playing the predominant role. Compared with BioNTech's RNA–lipoplex delivery platform, LLNPs demonstrated superior DC transfection, T cell activation, and antitumor efficacy. Collectively, these findings establish LLNPs as a robust and versatile platform for next-generation mRNA cancer vaccines with enhanced therapeutic potential.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114680"},"PeriodicalIF":11.5,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146098412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational m-PBPK Modeling reveals active transcytosis as the pivotal mechanism for nanoparticle tumor delivery: Implications for dose optimization","authors":"Jinwei Zhu ,&nbsp;Hui Lin ,&nbsp;Kejie Wang ,&nbsp;Sasa Zhang ,&nbsp;Hua He ,&nbsp;Kun Hao","doi":"10.1016/j.jconrel.2026.114684","DOIUrl":"10.1016/j.jconrel.2026.114684","url":null,"abstract":"<div><div>The long-held assumption that passive diffusion governs nanomedicine entry into the tumors has been increasingly challenged, with accumulating evidence implicating transcytosis as an important route for nanoparticle transport across the tumor endothelium. However, quantitative comparisons of their relative contributions remain scarce. To address this gap, this study developed a minimal physiologically based pharmacokinetic (m-PBPK) model that integrates in vitro cellular kinetic data to quantitatively describe to tumor delivery of nanoparticles and to assess the relative contributions of diffusion- and transcytosis-mediated transport within a model-based context. The framework was evaluated using PEGylated gold nanoparticles (AuNPs) spanning a range of particle sizes and incorporated empirical size-parameter relationships to enable in vitro<em>-</em>in vivo translational analysis. Model simulations suggested that transcytosis-mediated processes account for the majority of tumor AuNP accumulation under the modeled physiological conditions (99.0 %, 95 % CI: 94.7 %–99.8 %), whereas passive diffusion contributed a smaller fraction under most conditions examined. Dose-dependent analysis further indicated a capacity-limited tumor accumulation behavior, with a threshold around 18 mg, beyond which increasing the dose to 100 mg resulted in only a modest (∼15 %) increase in tumor accumulation. Sensitivity analyses indicated that systemic exposure and endothelial intracellular trafficking behavior are key determinants influencing tumor delivery, whereas enhanced intracellular sequestration consistently reduced tumor accumulation across dose levels. Overall, the proposed m-PBPK framework provides mechanistically interpretable, proof-of-concept insights into nanoparticle tumor delivery, supporting quantitative assessment of transcytosis efficiency and dose-dependent accumulation behavior for hypothesis generation in nanomedicine development.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114684"},"PeriodicalIF":11.5,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smart hypoxia-responsive sulfated polysaccharides liposomes for controlled and targeted urokinase delivery in thrombotic therapy","authors":"Dingfu Wang ,&nbsp;Dan Li ,&nbsp;Xiaolin Liu ,&nbsp;Shixin Wang ,&nbsp;Yile Fan ,&nbsp;Ling Lu ,&nbsp;Chuanbin Shen ,&nbsp;Chunxia Li","doi":"10.1016/j.jconrel.2026.114669","DOIUrl":"10.1016/j.jconrel.2026.114669","url":null,"abstract":"<div><div>Thrombosis remains a leading cause of cardiovascular and cerebrovascular mortality worldwide. Plasminogen activators, notably urokinase and alteplase, have been established as standard thrombolytic agents in clinical practice. However, their therapeutic potential is severely compromised by rapid metabolic clearance, non-specific biodistribution, and associated hemorrhagic complications. Here, we designed a dual-functional nano drug delivery platform that leverages P-selectin overexpression on activated platelets and the characteristic hypoxic microenvironment at thrombotic sites for precision thrombolytic intervention. Specifically, we developed a hypoxia-responsive block (PAC) by conjugating polyguluronate sulfate (PGS, P-selectin targeting motif) with azobenzene-modified cholesterol, enabling urokinase encapsulation within PAC@UK liposomes. Under hypoxic conditions that mimic the thrombotic microenvironment, the reductive cleavage of azobenzene moieties initiated sustained urokinase release (96.41% cumulative release), while maintaining exceptional biocompatibility and demonstrating preferential targeting of activated platelets. Comprehensive <em>in vivo</em> validation across zebrafish, murine mesenteric, and carotid artery thrombosis models revealed markedly enhanced thrombolytic efficacy compared to free UK. This biomimetic nanoplatform represents a paradigm shift toward intelligent, site-specific thrombolytic intervention, offering substantial clinical promise for safer and more effective treatment of thrombotic disorders.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114669"},"PeriodicalIF":11.5,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146089553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intranasal delivery of peptide-modified quercetin liposomes suppresses neuroinflammation","authors":"Changfeng Yin ,&nbsp;Guanglin Liu ,&nbsp;Xiqian Yuan ,&nbsp;Yumeng Zhang ,&nbsp;Yushan Tian ,&nbsp;Xiao Li ,&nbsp;Ling'e Zhang ,&nbsp;Xiqun Jiang ,&nbsp;Huan Chen ,&nbsp;Hongwei Hou ,&nbsp;Qingyuan Hu","doi":"10.1016/j.jconrel.2026.114678","DOIUrl":"10.1016/j.jconrel.2026.114678","url":null,"abstract":"<div><div>Neuroinflammation, a central pathological mechanism in central nervous system disorders, remains challenging to treat due to the restrictive nature of the blood-brain barrier and poor drug delivery efficiency. In this study, we developed a novel intranasal brain-targeted delivery system by constructing peptide-modified quercetin liposomes (QuR-lipo). By using intranasal administration to bypass the blood-brain barrier, QuR-lipo demonstrated higher uptake and accumulation in the brain compared to unmodified liposomes. This system disrupts the vicious cycle between neuroinflammation and oxidative stress, thereby improving neurobehavioral outcomes. QuR-lipo displayed a uniform particle size distribution, high encapsulation efficiency, and sustained-release characteristics. In vitro studies showed that QuR-lipo enhanced intracellular drug accumulation by modulating endocytic pathways, effectively inhibited aberrant microglial activation, suppressed pro-inflammatory cytokine cascades, and scavenged reactive oxygen species. In a lipopolysaccharide-induced neuroinflammation animal model, intranasal delivery of QuR-lipo significantly increased brain drug concentration, improved spatial memory deficits and depression-like behaviors, and suppressed microglial activation. Mechanistic studies revealed that QuR-lipo reversed neurological dysfunction by inhibiting the inflammasome signaling axis. Together, these findings provide an innovative strategy for brain-targeted delivery of natural bioactive compounds to treat neurodegenerative diseases.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"392 ","pages":"Article 114678"},"PeriodicalIF":11.5,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146089560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}